EICHORPublic-registry site landscape for NCT07748728, “TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs”, a Rheumatoid Arthritis (RA) study sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07748728 (registry record) |
| Study title | TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs |
| Sponsor | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| Condition(s) | Rheumatoid Arthritis (RA) |
| Phase | PHASE2 |
| Listed sites | 1 |
| Intervention(s) | TLL-018, Placebo |
| Site countries | China |
Patient-friendly overview of this study: eichor.com/study/NCT07748728.
Eichor generates a preliminary site-risk snapshot for NCT07748728 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
